Board
Screen
Heat
Cal
Watch
News
Blog
TV
News

CrossAmerica (CAPL) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

CrossAmerica (CAPL) has fallen 5.9% over the past four weeks, leaving the stock technically oversold and suggesting selling pressure may be exhausted. Wall Street analysts have…
Nov 5, 10:37 AM ·

Down 11.9% in 4 Weeks, Here's Why You Should You Buy the Dip in SM Energy (SM)

SM Energy (SM) has fallen 11.9% over the past four weeks, leaving the stock in technically oversold territory. Wall Street analysts have been raising earnings estimates in strong…
Nov 5, 10:37 AM ·

HCA Healthcare (HCA) Just Flashed Golden Cross Signal: Do You Buy?

HCA Healthcare (HCA) broke through its 20-day moving average, a technical signal suggesting a short-term bullish trend. The move follows the stock reaching a significant support…
Nov 5, 10:37 AM ·

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates

Lexicon Pharmaceuticals (LXRX) reported a Q3 loss of $0.03 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.04 loss a year ago, and also…
Nov 5, 10:37 AM ·

Injective (INJ), PEARL and Zcash (ZEC) Surge as Crypto Traders Return to Altcoins

Canary Capital's Staked INJ ETF (ticker INJC) has begun trading on Nasdaq, giving investors exposure to Injective's INJ token plus potential staking rewards through a standard…
Nov 5, 10:36 AM ·

Top Trending Cryptocurrencies Today: Pearl, Injective and Collector Crypt

Pearl, Injective (INJ) and Collector Crypt (CARDS) were among the top trending cryptocurrencies, with each rallying on separate catalysts. Pearl drew interest from traders tracking…
Nov 5, 10:34 AM ·

Eric Trump's American Bitcoin posts $126M Q3 profit, adds 425 BTC

American Bitcoin (NASDAQ: ABTC), co-founded by Eric Trump, reported $126 million in net income for Q3 2026, reversing a $52 million loss in the prior quarter, with most gains…
Nov 5, 10:34 AM ·

Ripple Says Crypto Mission Unchanged After Democrats Win House and Senate

Ripple CEO Brad Garlinghouse said the crypto industry's push for clear regulatory rules remains unchanged after Democrats won the House and Senate. Crypto PAC Fairshake won 29 of…
Nov 5, 10:28 AM

Fairchild Gold Identifies Two Additional Large Gold-Silver Target Areas at Golden Arrow as Hyperspectral Survey Highlights District-Scale Au-Ag-Related Alteration System

Fairchild Gold (TSXV: FAIR) said a TerraEye hyperspectral satellite survey over its Golden Arrow gold-silver project in Nevada identified 31 spectral alteration occurrences and…
Nov 5, 10:26 AM ·

Software Stock Eyes Best Day Since August After Blowout Q3

Unity Software (NYSE:U) shares jumped 10.7% to $47 in morning trading Thursday after the company reported third-quarter results that beat analyst estimates and issued…
Nov 5, 10:25 AM ·
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates
Nov 5, 10:37 AM·
Medium Optimistic

Sources

Summarized by i88

Tickers

Summary

Lexicon Pharmaceuticals (LXRX) reported a Q3 loss of $0.03 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.04 loss a year ago, and also topped revenue estimates for the quarter. On its Q3 earnings call, executives said the company expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes treatment.

Lexicon Pharmaceuticals Flags Two First-Quarter 2027 Milestones on Q3 Call

Lexicon Pharmaceuticals (NASDAQ: LXRX) expects two key milestones in the first quarter of 2027, executives said on the company’s third-quarter earnings call, according to MarketBeat.

What to Expect

The two milestones cited on the call are:

  • Results from a pivotal heart disease trial.
  • A resubmission of the company’s application for a type 1 diabetes treatment.

Q3 Results in Brief

Lexicon reported a third-quarter loss of $0.03 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.04 loss a year ago. The company also topped revenue estimates for the quarter.

Context

The earnings call remarks place both the heart disease trial readout and the type 1 diabetes application resubmission in the same quarter, giving investors two potential catalysts to watch in early 2027.